Beyond their well-known applications in bone tissue engineering, hydroxyapatite
nanoparticles (HAp NPs) have also been showing great promise for improved cancer …

Background To date, standardising clinical predictive biomarkers for assessing the response
to immunotherapy remains challenging due to variations in personal genetic signatures …

Abstract Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic
landscape of patients with lung cancer. However, only a subset of them derived clinical …

Importance Hyperprogressive disease (HPD) is a recognized pattern of rapid tumor
progression during immune checkpoint inhibitor (ICI) treatment. Definitions of HPD have not …

Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly
based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination …

Background: There are conflicting data on the effects of dysbiosis-inducing drugs, and
especially antibiotics (ATBs), on clinical outcomes in patients treated with immune …

Simple Summary Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of
advanced non-small-cell lung cancer (NSCLC) leading to substantial improvement in …

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and
improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard …

C. citratus essential oil and carvacrol have shown an antitumor effect on breast tumor cell
lines; the main objective of this research was to evaluate the antitumor effect of the essential …

Despite the relevant antitumor efficacy of immunotherapy in advanced non-small cell lung
cancer (NSCLC), the results in patients whose cancer harbors activating epidermal growth …